Search Results - "EHLHARDT, W. J"

Refine Results
  1. 1

    Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979 by DANTZIG, A. H, SHEPARD, R. L, CAO, J, LAW, K. L, EHLHARDT, W. J, BAUGHMAN, T. M, BUMOL, T. F, STARLING, J. J

    Published in Cancer research (Chicago, Ill.) (15-09-1996)
    “…Overexpression of P-glycoprotein (Pgp) by tumors results in multidrug resistance (MDR) to structurally unrelated oncolytics. MDR cells may be sensitized to…”
    Get full text
    Journal Article
  2. 2

    Sulfonimidamide analogs of oncolytic sulfonylureas by TOTH, J. E, GRINDEY, G. B, WEIR, L. C, WORZALLA, J. F, EHLHARDT, W. J, RAY, J. E, BODER, G. B, BEWLEY, J. R, KLINGERMAN, K. K, GATES, S. B, RINZEL, S. M, SCHULTZ, R. M

    Published in Journal of medicinal chemistry (14-03-1997)
    “…A series of sulfonimidamide analogs of the oncolytic diarylsulfonylureas was synthesized and evaluated for (1) in vitro cytotoxicity against CEM cells, (2) in…”
    Get full text
    Journal Article
  3. 3

    Metabolism and Disposition of the Antifolate LY231514 in Mice and Dogs by WOODLAND, J. M, BARNETT, C. J, DORMAN, D. E, GRUBER, J. M, SHIH, C, SPANGLE, L. A, WILSON, T. M, EHLHARDT, W. J

    Published in Drug metabolism and disposition (01-06-1997)
    “…The metabolism and disposition of LY231514 was studied in mice and dogs. LY231514 is a novel pyrrolopyrimidine-based multi-target antifolate (MTA) showing…”
    Get full text
    Journal Article
  4. 4

    Metabolism and disposition of the anticancer agent sulofenur in mouse, rat, monkey, and human by Ehlhardt, W J

    Published in Drug metabolism and disposition (01-03-1991)
    “…The elimination and metabolism of sulofenur [N-(5-indanesulfonyl)-N'-(4-chlorophenyl)urea, LY186641] was examined in mice, rats, monkeys, and humans. The…”
    Get more information
    Journal Article
  5. 5

    Metabolism and disposition of p-chloroaniline in rat, mouse, and monkey by Ehlhardt, W J, Howbert, J J

    Published in Drug metabolism and disposition (01-03-1991)
    “…The metabolism and disposition of [14C]p-chloroaniline was studied in the male Fisher 344 rat, female C3H mouse, and male rhesus monkey. Greater than 90% of…”
    Get more information
    Journal Article
  6. 6
  7. 7

    Characterization of an O-glucuronide metabolite of the CCK-B antagonist LY288513 and its plasma levels in mouse, rat, and dog by Woodland, J M, Ehlhardt, W J

    Published in Drug metabolism and disposition (01-09-1995)
    “…LY288513 [(4S,5R)-trans-N-(4-bromophenyl)-3-oxo-4,5-diphenyl-1- pyrazolidinecarboxamide] has been developed as a cholecystokinin-B antagonist for anxiolytic…”
    Get more information
    Journal Article
  8. 8

    Biotransformation of the antiviral agent 1,3,4-thiadiazol-2-ylcyanamide (LY217896) and characteristics of a mesoionic ribose metabolite by Ehlhardt, W J, Wheeler, W J, Breau, A P, Chay, S H, Birch, G M

    Published in Drug metabolism and disposition (01-01-1993)
    “…The biotransformation of the antiinfluenza agent 1,3,4-thiadiazol-2-ylcyanamide (LY217896, I) was studied. In addition to a urea metabolite (II) formed by…”
    Get more information
    Journal Article
  9. 9

    Disposition and metabolism of the Sulfonylurea Oncolytic Agent LY295501 in Mouse, Rat, and Monkey by EHLHARDT, W. J, WOODLAND, J. M, TOTH, J. E, RAY, J. E, MARTIN, D. L

    Published in Drug metabolism and disposition (01-06-1997)
    “…The disposition and metabolism of LY295501 was studied in mice, rats, and monkeys. This novel diaryl sulfonylurea oncolytic agent is structurally related to…”
    Get full text
    Journal Article
  10. 10
  11. 11
  12. 12

    Thiol-mediated incorporation of radiolabel from 1-[14C]-methyl-4-phenyl-5-nitrosoimidazole into DNA. A model for the biological activity of 5-nitroimidazoles by Ehlhardt, W J, Goldman, P

    Published in Biochemical pharmacology (01-04-1989)
    “…1-Methyl-4-phenyl-5-nitrosoimidazole (5NO), which has properties consistent with the biologically active form of a 5-nitroimidazole, was radiolabeled…”
    Get more information
    Journal Article
  13. 13

    Comparison of metabolism and toxicity to the structure of the anticancer agent sulofenur and related sulfonylureas by Ehlhardt, William J, Woodland, Joseph M, Worzalla, John F, Bewley, Jesse R, Grindey, Gerald B, Todd, Glen C, Toth, John E, Howbert, J. Jeffry

    Published in Chemical research in toxicology (01-09-1992)
    “…The metabolic formation of p-chloroaniline from the oncolytic agent sulofenur [N-(5-indanesulfonyl)-N'-(4-chlorophenyl)urea, LY186641,] and from similar…”
    Get full text
    Journal Article
  14. 14

    Pharmacokinetics of the anticancer agent sulofenur in mice, rats, monkeys, and dogs by Ehlhardt, W J, Sullivan, H R, Wood, P G, Woodland, J M, Hamilton, M, Hamilton, C, Cornpropst, D, Grindey, G B, Worzalla, J F, Bewley, J R

    Published in Journal of pharmaceutical sciences (01-07-1993)
    “…The absorption and pharmacokinetics of sulofenur [N-(indan-5-sulfonyl)-N'-(4-chlorophenyl)urea, LY186641] and its major metabolites were examined in mice,…”
    Get more information
    Journal Article
  15. 15

    Formation of an amino reduction product of metronidazole in bacterial cultures: lack of bactericidal activity by Ehlhardt, W J, Beaulieu, Jr, B B, Goldman, P

    Published in Biochemical pharmacology (15-01-1987)
    “…To investigate whether the amino reduction product of metronidazole has antibacterial activity, 5-amino-1-beta-hydroxyethyl-2-methylimidazole (AMN) was…”
    Get more information
    Journal Article
  16. 16

    Glutathione-Dependent Metabolism of the Antitumor Agent Sulofenur. Evidence for the Formation of p-Chlorophenyl Isocyanate as a Reactive Intermediate by Jochheim, Claudia M, Davis, Margaret R, Baillie, Kathleen M, Ehlhardt, William J, Baillie, Thomas A

    Published in Chemical research in toxicology (01-02-2002)
    “…The antitumor agent sulofenur (LY186641), which has shown promising activity against a wide range of cancers, causes hemolytic anemia and methemoglobinemia at…”
    Get full text
    Journal Article
  17. 17

    Mammalian cell toxicity and bacterial mutagenicity of nitrosoimidazoles by Ehlhardt, W J, Beaulieu, Jr, B B, Goldman, P

    Published in Biochemical pharmacology (01-07-1988)
    “…It is currently believed that the biological activity of such therapeutic 5-nitroimidazoles as metronidazole is mediated by a short-lived, highly toxic species…”
    Get more information
    Journal Article
  18. 18

    Chemical and biological properties of acetyl derivatives of the hydroxylamino reduction products of metronidazole and dimetridazole by Ehlhardt, W J, Beaulieu, Jr, B B, Goldman, P

    Published in Biochemical pharmacology (15-03-1987)
    “…Metronidazole and related 5-nitroimidazoles undergo reduction of their nitro group apparently to produce such reactive species as 5-hydroxylaminoimidazoles. To…”
    Get more information
    Journal Article
  19. 19

    Binding of the epoxide cryptophycin analog, LY355703 to albumin and its effect on in vitro antiproliferative activity by Schultz, R M, Shih, C, Wood, P G, Harrison, S D, Ehlhardt, W J

    Published in Oncology reports (01-09-1998)
    “…Cryptophycin, isolated from the cyanobacterium Nostoc, is a cytotoxic dioxadiazacyclohexadecenetetrone which causes rapid depletion of microtubules in intact…”
    Get more information
    Journal Article
  20. 20

    Novel acid labile COL1 trityl-linked difluoronucleoside immunoconjugates: synthesis, characterization, and biological activity by Patel, V F, Hardin, J N, Mastro, J M, Law, K L, Zimmermann, J L, Ehlhardt, W J, Woodland, J M, Starling, J J

    Published in Bioconjugate chemistry (01-07-1996)
    “…LY207702 (1) is a difluorinated purine nucleoside that exhibits impressive antitumor activity in preclinical models. This agent, however, also possesses…”
    Get full text
    Journal Article